# A Study of High-Risk Oral Cavity Cancer

> **NCT00934739** · PHASE2,PHASE3 · TERMINATED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 150 (actual)

## Conditions studied

- Oral Cavity Cancer

## Interventions

- **DRUG:** Thalidomide, Celebrex
- **DRUG:** Cyclophosphamide, Dexamethasone

## Key facts

- **NCT ID:** NCT00934739
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934739, "A Study of High-Risk Oral Cavity Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00934739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*